Krka d. d Inkomsten in het verleden
Verleden criteriumcontroles 5/6
Krka d. d is de winst gegroeid met een gemiddeld jaarlijks percentage van 7.5%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 13.1%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 5.1% per jaar. Het rendement op eigen vermogen van Krka d. d is 15.2%, en het heeft een nettomarge van 19.6%.
Belangrijke informatie
7.5%
Groei van de winst
8.1%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 12.4% |
| Inkomstengroei | 5.1% |
| Rendement op eigen vermogen | 15.2% |
| Nettomarge | 19.6% |
| Volgende winstupdate | 14 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Krka, d. d.'s (LJSE:KRKG) Shareholders Might Be Looking For Exit
Aug 27
Should You Be Adding Krka d. d (LJSE:KRKG) To Your Watchlist Today?
Aug 09Krka d. d (LJSE:KRKG) Is Paying Out A Larger Dividend Than Last Year
Jul 22Krka d. d (LJSE:KRKG) Will Pay A Larger Dividend Than Last Year At €7.50
Jun 11Are Investors Undervaluing Krka, d. d. (LJSE:KRKG) By 38%?
Jan 31There's Reason For Concern Over Krka, d. d.'s (LJSE:KRKG) Price
Jan 09Is Krka, d. d. (LJSE:KRKG) Trading At A 24% Discount?
Aug 05Krka d. d (LJSE:KRKG) Is Increasing Its Dividend To €6.60
Jul 14Does Krka d. d (LJSE:KRKG) Deserve A Spot On Your Watchlist?
May 24Krka d. d (LJSE:KRKG) Has Announced That It Will Be Increasing Its Dividend To €6.60
Apr 09Krka, d. d.'s (LJSE:KRKG) Intrinsic Value Is Potentially 25% Above Its Share Price
Jan 27Is There An Opportunity With Krka, d. d.'s (LJSE:KRKG) 48% Undervaluation?
Oct 26Here's Why We Think Krka d. d (LJSE:KRKG) Might Deserve Your Attention Today
Aug 30Krka d. d (LJSE:KRKG) Is Paying Out A Larger Dividend Than Last Year
Jun 24Is Now The Time To Put Krka d. d (LJSE:KRKG) On Your Watchlist?
May 19Krka d. d's (LJSE:KRKG) Upcoming Dividend Will Be Larger Than Last Year's
Apr 28If You Like EPS Growth Then Check Out Krka d. d (LJSE:KRKG) Before It's Too Late
Feb 14Are Investors Undervaluing Krka, d. d. (LJSE:KRKG) By 49%?
Nov 24Here's Why We Think Krka d. d (LJSE:KRKG) Is Well Worth Watching
Oct 30Are Investors Undervaluing Krka, d. d. (LJSE:KRKG) By 49%?
Aug 11Increases to Krka, d. d.'s (LJSE:KRKG) CEO Compensation Might Cool off for now
Jul 02Are Investors Undervaluing Krka, d. d. (LJSE:KRKG) By 43%?
Mar 30Is It Worth Buying Krka, d. d. (LJSE:KRKG) For Its 4.4% Dividend Yield?
Mar 11Krka, d. d.'s (LJSE:KRKG) Stock Has Fared Decently: Is the Market Following Strong Financials?
Feb 22What You Need To Know About Krka, d. d.'s (LJSE:KRKG) Investor Composition
Feb 03
Shareholders Of Krka d. d (LJSE:KRKG) Must Be Happy With Their 93% Return
Jan 14Calculating The Fair Value Of Krka, d. d. (LJSE:KRKG)
Dec 27Does Krka, d. d. (LJSE:KRKG) Have A Place In Your Dividend Portfolio?
Dec 09Could The Market Be Wrong About Krka, d. d. (LJSE:KRKG) Given Its Attractive Financial Prospects?
Nov 20Opbrengsten en kosten
Hoe Krka d. d geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 1,871 | 366 | 471 | 185 |
| 31 Mar 24 | 1,834 | 324 | 459 | 182 |
| 31 Dec 23 | 1,806 | 314 | 455 | 179 |
| 30 Sep 23 | 1,816 | 298 | 435 | 170 |
| 30 Jun 23 | 1,780 | 298 | 447 | 167 |
| 31 Mar 23 | 1,743 | 362 | 454 | 165 |
| 31 Dec 22 | 1,717 | 363 | 440 | 163 |
| 30 Sep 22 | 1,631 | 369 | 440 | 161 |
| 30 Jun 22 | 1,615 | 367 | 420 | 160 |
| 31 Mar 22 | 1,602 | 313 | 401 | 157 |
| 31 Dec 21 | 1,566 | 309 | 393 | 155 |
| 30 Sep 21 | 1,551 | 320 | 369 | 154 |
| 30 Jun 21 | 1,540 | 308 | 369 | 155 |
| 31 Mar 21 | 1,468 | 292 | 365 | 155 |
| 31 Dec 20 | 1,535 | 291 | 378 | 153 |
| 30 Sep 20 | 1,563 | 284 | 407 | 154 |
| 30 Jun 20 | 1,536 | 267 | 422 | 152 |
| 31 Mar 20 | 1,578 | 261 | 431 | 154 |
| 31 Dec 19 | 1,493 | 246 | 434 | 152 |
| 30 Sep 19 | 1,451 | 226 | 441 | 146 |
| 30 Jun 19 | 1,414 | 213 | 427 | 143 |
| 31 Mar 19 | 1,372 | 196 | 427 | 136 |
| 31 Dec 18 | 1,332 | 175 | 420 | 131 |
| 30 Sep 18 | 1,310 | 163 | 419 | 128 |
| 30 Jun 18 | 1,291 | 163 | 413 | 126 |
| 31 Mar 18 | 1,283 | 159 | 411 | 126 |
| 31 Dec 17 | 1,266 | 153 | 414 | 126 |
| 30 Sep 17 | 1,250 | 138 | 410 | 126 |
| 30 Jun 17 | 1,226 | 130 | 405 | 121 |
| 31 Mar 17 | 1,195 | 111 | 408 | 120 |
| 31 Dec 16 | 1,174 | 108 | 394 | 118 |
| 30 Sep 16 | 1,154 | 105 | 389 | 116 |
| 30 Jun 16 | 1,169 | 116 | 387 | 118 |
| 31 Mar 16 | 1,176 | 143 | 380 | 117 |
| 31 Dec 15 | 1,165 | 158 | 387 | 115 |
| 30 Sep 15 | 1,197 | 172 | 405 | 114 |
| 30 Jun 15 | 1,192 | 172 | 406 | 111 |
| 31 Mar 15 | 1,183 | 179 | 413 | 111 |
| 31 Dec 14 | 1,192 | 166 | 407 | 108 |
| 30 Sep 14 | 1,201 | 175 | 390 | 99 |
| 30 Jun 14 | 1,203 | 179 | 391 | 99 |
| 31 Mar 14 | 1,204 | 164 | 389 | 98 |
| 31 Dec 13 | 1,201 | 173 | 393 | 97 |
Kwaliteitswinsten: KRKG heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (19.6%) KRKG } zijn hoger dan vorig jaar (16.7%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van KRKG is de afgelopen 5 jaar met 7.5% per jaar gegroeid.
Versnelling van de groei: De winstgroei van KRKG over het afgelopen jaar ( 23% ) overtreft het 5-jarig gemiddelde ( 7.5% per jaar).
Winst versus industrie: De winstgroei KRKG over het afgelopen jaar ( 23% ) overtrof de Pharmaceuticals -sector 4.5%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 15.2% ) van KRKG wordt als laag beschouwd.